ved for use through 10/31/2002. OMB 0651-0032 coffice: U.S. DEPARTMENT OF COMMERCE

Patent and Tra Under the Paperwork Reduction act of 1995, no persons are required to re-

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Title		Compositions for Rapid Protein and Peplido d Isolation Using a Lysis Matrix				
First Inventor		Robert W. Blakesley				
Attorney Docket No.		0942.5050002/RWE/AGL				
spond to	a collection of infoni	nation unless it displays a valid OMB control number.				

	<u> </u>			ت									
	PTO	APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent applicat		ΑL	DR	ESS TO:	Assistant C Box Patent Washington	Appl					
	 □ □ □ 	Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. Specification [Total Pages 65]		 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: 									
True B W. Werts. Work, M. M.	ini 'ini' 'ini' 'ini'	(preferred arrangement set forth below) - Descriptive title of the Invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	1 Sheets 13] 1 Pages] 1	i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. 7 37 CFR 3.73(b) Statement Power of Attorney							06/60		
other forth ling	1	Drawing(s) (35 U.S.C. 113) [Total Sheets 13 th or Declaration [Total Pages] a. ☐ Newly executed (original or copy) b. ☐ Copy from a prior application (37 CFR (for continuation/divisional with Box 18 com		11. 12.		(when there English Tr	is an assignee)	assignee) ution Document (if applicable)					
4 4	. I			13.		Statement Preliminar	Copies of IDS Citations						
1 1 1 1 1	H HAR JUG	 DELETION OF INVENTOR Signed statement attached deleti named in the prior application, s 1.63(d)(2) and 1.33(b). 			 14.								
-	6. 🖸 Application Data Sheet. See 37 CFR 1.76.				 (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. Other: Authorization under 37 C.F.R. § 1.136(a)(3) ✓ Other: The name of the assignee is: Invitrogen Corporation 								
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-Part (CIP) of prior application No:/													
19. CORRESPONDENCE ADDRESS													
Customer Number or Bar Code Label Customer No. 26111 (Insert Customer No. or Atta						or Correspondence address below							
NAME STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. Attorneys at Law ADDRESS Suite 600, 1100 New York Avenue, N.W.													
CITY Washington STATE COUNTRY USA TELEPHON			STATE TELEPHONE	DC ZIP CODE (202) 371-2600 FAX					20005-3934 (202) 371-2540				
	NAME (Print/Type) Robert W. Esmond Registration No. (Attorney/Agent) 32,893												
	SIGNA	TURE KOLOTATU SO	nens					- 1	Date Jules 1	3.200	/		